AZN•benzinga•
IMFINZI Plus Chemotherapy Further Improved Overall Survival Benefit In Advanced Biliary Tract Cancer In The TOPAZ-1 Phase III Trial, Reducing The Risk Of Death By 24% In Additional Follow-up; Will Present At ESMO
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga